J (@jayabacus) header
J (@jayabacus) profile picture

There isn't a day that goes by that I don't think about the 3 L's from Charlie! Good luck boys!

FL, USA
Joined September 2012
Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)
Elon Musk predicts Tesla's Optimus will be able to do household chores in 12 to 18 months, but says its first job will be heavy industry: “Picking up, say, a plate that’s still got food remnants on it… wiping the food off the plate, putting it under the sink, washing it, drying it, and then putting it safely back in the closet. There’s no humanoid robot that can do that at all.” “I think Optimus will be able to do it in 12 to 18 months.” “Optimus could be many things. It could be a teaching tutor for your kids. It could be a babysitter, watch over, protect your kids, make sure they’re okay, and teach them things. It could mow the lawn… cook dinner.” “Most people would love to have their own personal R2-D2, C-3PO, but that’s even more useful than that.” So what’s the highest and best use at first? “It would probably be heavy industry. So, like mining and refining ore.” “The United States has a very high degree of dependence on other countries for mining and refining ore. And I think we need to make sure for our national security that we can do so within the country.” “Once you get through those 24/7, kind of heavy industry jobs, at some point it’ll make sense for people to have one in their home. And I think pretty much everyone’s going to want one, if not two.”
140
367
26
2,864
185,849
$MDT - NEEDHAM basically calling out $MDT you need $AVR more then ever to compete ??🤷‍♂️ note that MDT has seen some pressure on its transcatheter aortic valve replacement (TAVR) business due to 6-7 year data from the Evolut Low Risk trial that showed a higher reintervention rate compared to surgery (5.5% vs. 3.3% at 6 years) which was driven by aortic regurgitation. Management noted that while this hurt US TAVR growth initially, they have seen procedure volumes stabilize. On our recent cardiology expert call, Dr. Andrew Goldsweig indicated that the market increasingly favors balloon-expandable TAVR designs and that Edwards Lifesciences' (EW - Not Covered) currently has the best TAVR and that MDT is at risk of market share loss until it launches its own balloon-expandable TAVR.
5
4
1
17
7,732
Amidst all the chaos that happened in the past few days, this makes me feel proud of humanity.
After careful consideration I’ve decided I’m quite bullish on civilization KARDASHEV II HERE WE COME!
96
228
6
3,046
451,574
2015. Bernie Sanders: Open borders is a right wing proposal to bring in cheap labor. Immigration makes Americans poorer. Bernie says the complete opposite today. What a fraud.
1,127
12,958
1,059
49,257
1,427,202
$NKTR OPPY PT $140 Off-treatment AD data in 1Q27 could further differentiate rezpeg’s durability. NKTR plans to assess clinical responses through 52-weeks after treatment cessation, following one full year of therapy. Mgt highlighted ~50% EASI-75 retention at 12-months as potentially differentiated vs. dupilumab’s nine- month withdrawal data. believe sustained responses could support quarterly maintenance, with 6-month dosing potentially appropriate for deep responders, pending further clinical evaluation.
My outlook on $NKTR. Still own shares - disappointing performance in 2H26 no doubt, though nothing really changed fundamentally in that time period either. The AA update was an incremental and hard to interpret dataset that was treated realistically more like a liquidity event. Similarly, the AtD off-treatment update in 1H27 is unlikely to be anything seismic. Maybe a bit more informative than AA off treatment data, but I don't think it's going to make or break anyone's thesis. The setup from here is pretty simple...Viable drug with unique MoA in 1 HUGE market and 1 mid size market that has very weak competition. Dual indication derm launch with a unique MoA in a safe biologic with Q3M dosing? There's value there. Now, of course, we have to see that safety stays on track through all these P3 studies. There doesn't seem to be any whiff of safety concern so far, so that's encouraging, but they run these studies for a reason - you never know! We ultimately have to see safety hold up for this to work long term. Efficacy so far looks worse than IL4/13, obviously, which some people really get hung up on. Such a myopic view is hard for me to grasp, because the pitch here has *long* (always?) been use in patients for whom dupi/lebri/adbry/$APGE/$KYMR drugs don't work...which is about half of atopic derm patients...And yes, those drugs are *all* on the exact same mechanistic axis. There's really only one drug on the market today that ISN'T on that axis...Nemluvio. Its efficacy is terrible, yet it is going to be a multi-blockbuster drug. Rezpeg so far is showing much better efficacy, much sparser dosing, and potential to enter a secondary indication that is much larger than nemluvio's and where it will compete only with JAK inhibitors...not with the king dupixent like Nemluvio has to battle in PN. "It's worse than dupi" is an unbelievably stupid and uninformed bear thesis, but I have heard it regularly for 2 years straight...whatever. Everybody seemed to understand the *differentiated MoA* argument for OX40 drugs when $AMGN and $SNY were saying these things were gonna generate tens of billions of dollars in revenue...not sure why it is so hard to understand now for Rezpeg? Not sure why its so universal to completely ignore Nemluvio's success as a *vastly* inferior drug with an alternative MoA? 🤷‍♂️ Down the road more competition will emerge, likely including bispecifics that hopefully bring us something other than IL4/13/STAT6. Still, Rezpeg is well on its way to be *years* ahead of them in getting to market. Getting entrenched as a drug with a safe, effective, unique MoA drug with a Q3M dosing interval...to me that looks like an eventuality *if* the P3 data hold up similar to P2. Another note - $NKTR is currently the ONLY company running a biologic refractory phase 3 in atopic derm. That hitting would be a MASSIVE advantage for them in competitng with other drugs, being the *only* option labeled for use in patients who have failed other biologics...which, given the size of and response rates in AtD, would still potentially be one of the top 5 biggest opportunity in all of I&I...The market opportunity here is just absurdly big. AA P3 will, in my opinion, hit, making Rezpeg the first and only safe biologic approved for that disease. The JAK inhibitors see little use there because it is a borderline cosmetic condition of hair loss...many providers and patients are not willing to take the (potentially fatal) labeled risks that come on the JAK inhibitors' black box warning. Again we here the uninformed "but it is less effective than the JAKs" argument from the bears. This argument couldn't possibly be more debunkable...look at Atopic dermatitis as your exemplar - the JAK inhibitors are nearly 2x more effective than the IL4/13 inhibitors, yet the 4/13 inhibitors get used 10x more than the JAKs...DERMATOLOGISTS CHOOSE THE SAFEST DRUG FIRST, PERIOD. The same WILL be the case in alopecia areata, meaning that if Rezpeg succeeds there, it will dominate the AA market until another safe biologic comes along that's better. And I wouldn't hold my breath waiting for that given the many failures (including dupixent) that we have seen in that space. Anyway, I'm not "pounding the table" here by any means. But, $NKTR trading near cash at this stage still feels like very solid risk/reward skew. If the P3 trials reproduce near the efficacy they showed in P2 and the drug remains safe in these larger/longer datasets, they've got a window to have blockbuster launches in 2 derm indications at once. That's pretty rare, and I can't imagine it wouldn't attract significant pharma/investor interest. Risks remain OBVIOUSLY. There is no guarantee of a happy ending to any story where 4 P3 trials still await results. But when you're paying just a little more than cash on hand for a drug with a unique MoA, sparse dosing, and a record of meaningful efficacy and safety in 2 large TAMs (including AtD, *the* largest TAM in all of I&I)...that seems like a decent deal to me, even if the market is going to treat it like "dead money" for a while.
2
1
42
6,209
38% of TAVR pts left with PPM. Severe PPM pts felt as good as everyone at 1 yr, then by 3 yrs only 31% were alive & well vs 49%. The damage shows up late, and the younger the patient, the more years it has to show up. $AVR DurAVR: 0% severe PPM in small and medium annuli so far.
🫀New in #JACCINT: Severe prosthesis–patient mismatch (PPM) after #TAVR was linked to worse 3-year health status! 📉 Only 30.6% achieved good health vs 49.4% without PPM. ⚠️ Residual MR may contribute. 🩺 Patient-centered outcomes matter! ❤️🏥📊 bit.ly/4kPuqVC #vhdMR
2
1
11
1,506
$NKTR BRiley BUY PT $150 3Q results were ahead of Street on lower R&D, YE26 cash guidance moved above $840M with runway into 3Q28. •1Q27 off-treatment AtD readout is only efficacy dataset in the next 12 months, and expect roughly half to 60% of responders to hold EASI-75 a year after stopping Rezpeg, supporting quarterly dosing. ZENITH-AD remains on track for summer 2028 topline, ZENITH-AA now starts in December vs. early 2027, and a vitiligo PoC study adds a second JAK-only market. EV has compressed to ~$0.3B against $953M in cash, heavily discounting ~$2B 2034 risk-adjusted revenue forecast.
$NKTR ZENITH-AD 2. Based on regulatory feedback, ZENITH-AD 2 (previously planned as a 2nd monotherapy trial in biologic/JAKi naive pts) will now include background TCS & enroll both biologic/JAKi naive and experienced participants. All three ZENITH-AD trials — ZENITH-AD 1 (monotx, naive), 2 (in combination with TCS), a 3 (biologic/JAKi experienced) have now been initiated
1
5
31
4,835
Adam Destroys Gavin Newsom !
53
1,255
19
7,326
336,169
Replying to @semodough
Cowen's own $EW bull note: AS should be judged by "myocardial damage and functional impairment," not just the valve. Moderate AS could grow TAVR 1.5×. Agreed. LANDMARK: damage drives mortality. Garg MRI: DurAVR normalizes flow, and flow predicts LV regression. $AVR 🤷‍♂️
1
1
5
727
NOW WE KNOW WHY FLORIDA ISN'T GOING BLUE: Florida passed its own version of the SAVE Act earlier this year. It requires citizenship verification using REAL ID data for voter registrations and mandates paper ballots. The measure also requires federal candidates to disclose stock trading while in office and sets a five year statute of limitations for felony election offenses. The bill cleared both chambers with Republican majorities before being signed in April.
119
890
31
3,637
158,668
Can you imagine if Musk didn’t buy X. There would be nothing but Liberal propaganda everywhere. Thanks Elon for saving free speech
329
1,661
53
23,006
197,112
Does earlier TAVR simply start the reintervention clock sooner? Dr @nmbutala explains why early TAVR remained highly cost-effective even when future reintervention was modelled ▶️ More from #TCT2026 on our TCT Congress Hub 👉 radc.life/HX44ldGp #TAVR #AorticStenosis
2
4
383
🚨 BREAKING: Elon Musk has OFFICIALLY been invited to relocate its Tesla headquarters from Texas to the free state of FLORIDA ☀️ And the invite points STRAIGHT to the fact Democrats won Texas Gov. Ron DeSantis has also warned that Elon may soon be TARGETED because of the election results REP. CARLOS GIMENEZ: "While others seek to investigate and punish success, Florida welcomes it." "I write to formally invite Tesla to consider relocating its corporate headquarters and expanding its operations from Texas to the free State of Florida, where innovation, entrepreneurship, and economic freedom are celebrated." "With the recent election of self-described Democratic Socialists to positions of power in Texas, I share your concerns about excessive government interference, politically motivated investigations, and policies that punish success." "No company should face political retaliation for creating jobs, investing in American innovation, and contributing to our nation's prosperity." "The Sunshine State is open for business." Musk already took his companies OUT of California because of hostile politics If Texas starts heading down that same road, Florida is ready!
2,336
9,038
410
50,437
2,862,536
J retweeted
US water use per year: Data centers: ~17 billion gallons Golf courses: ~500 billion gallons Farm irrigation: ~27 trillion gallons
59
291
41
1,138
53,931
Scott Galloway is upset that our parents are taking too long to die. “Quite frankly our parents are living too damn long. Great, I'm going to get a house when I'm 80 and they're 100.” Something is seriously wrong with these people.
1,768
993
375
6,362
778,357
Scott Galloway says he owned a Tesla, but sold it because of Elon. "Not before taking a giant dump in the passenger seat. True story." He's gone from suggesting Elon be executed to telling stories of taking dumps in a car he owned because it was made by Elon's company. This is a broken, deranged and utterly toxic individual.
2,294
1,390
724
10,240
3,158,901
We got Jay Leno to try $TSLA FSD once and for all.
3
2
39
3,676